, /PRNewswire/ -- , a digital health company pioneering a new class of treatments for neuro-visual disorders, today announced that real-world data (RWD) from the Patients Using Prescription Luminopia (PUPiL) RegistryTM continues to demonstrate efficacy of the FDA-approved therapy in improving vision for children with amblyopia. approach to treating amblyopia, or lazy eye, in young children – pairing proprietary therapeutic software with virtual reality (VR) headsets and popular children's TV shows – has been available on the market for over a year following rigorous clinical trials and de novo . The data presented at the European and International Strabismological Association conference in by , MD, FAAO, Professor, , further support the topline data presented at recent international scientific meetings.
Results from the PUPiL Registry were first presented at the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2024 annual meeting in April by , MD, Clinical Associate Professor of Ophthalmology, and then at the Association for Research in Vision and Ophthalmology (ARVO) 2024 annual meeting in May, by , MD, at the Cole Eye Institute, Cleveland Clinic. This initial registry analysis of 179 patients from 10 clinical sites showed significant improvement in visual acuity after 12 weeks of Luminopia treatment in a broad population. The cohort of patients with similar baseline characteristics to Luminopia clinical trial participants improved by 1.
7 lines in .
